Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) has issued an update.
Jenscare Scientific Co., Ltd. announced the six-month clinical follow-up results for its LuX-Valve Plus transcatheter tricuspid valve replacement, demonstrating significant efficacy and safety for patients with large annulus. The study, presented at PCR London Valves 2025, highlights the device’s high success rate and improvements in patients’ cardiac function and quality of life, addressing a critical gap in treatment options for this patient group.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the medical device industry. The company specializes in developing innovative transcatheter heart valve replacement solutions, particularly targeting unmet clinical needs in patients with severe tricuspid regurgitation and high surgical risk.
Average Trading Volume: 768,217
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.67B
For a thorough assessment of 9877 stock, go to TipRanks’ Stock Analysis page.